KLF12 Antibody

What is KLF12 and what are its key biological functions?

KLF12 (Krüppel-like factor 12) is a transcription factor belonging to the Sp1 C2H2-type zinc-finger protein family. It contains three C2H2-type zinc fingers and functions primarily as a transcriptional regulator. KLF12 confers strong transcriptional repression to the AP-2-alpha gene by binding to a regulatory element (A32) in its promoter .

Key biological functions of KLF12 include:

• Transcriptional regulation of genes involved in cancer progression

• Modulation of immune checkpoint molecules (PD-L1)

• Regulation of cardiac remodeling processes

• Control of cell proliferation and apoptosis pathways

What is the subcellular localization of KLF12 and how does this impact antibody selection?

KLF12 primarily localizes to the nucleus, consistent with its function as a transcription factor . This nuclear localization is critical for its ability to bind to promoter regions and regulate gene expression.

When selecting KLF12 antibodies, consider the following localization-related factors:

Immunofluorescence studies using KLF12 antibodies show clear nuclear staining patterns. For example, PFA-fixed, Triton X-100 permeabilized SH-SY5Y cells stained with ab221602 at 4 μg/ml demonstrate specific nuclear localization of KLF12 . Similarly, KLF12 detection in HEK293 cells using MAB9097 shows specific staining localized to nuclei .

What is the molecular weight of KLF12 and why might discrepancies be observed?

This molecular weight discrepancy can be attributed to several factors:

• Post-translational modifications (phosphorylation, SUMOylation, glycosylation)

• Protein-protein interactions that persist despite denaturing conditions

• Structural characteristics affecting migration in SDS-PAGE

• Presence of multiple isoforms (at least three isoforms have been reported)

When performing Western blot analysis with KLF12 antibodies, it's essential to anticipate this discrepancy and use appropriate molecular weight markers and positive controls. For instance, Western blot data using ab129459 demonstrates detection of KLF12 at higher molecular weight across multiple cell types (Jurkat, 293T, HeLa) .

How can KLF12 antibodies be utilized to investigate its role in cancer immunology?

KLF12 has emerged as a key regulator of PD-L1 expression in non-small cell lung cancer (NSCLC), making it a target of interest in cancer immunology research. KLF12 antibodies can be utilized in several sophisticated approaches:

Transcriptional Regulation Studies:

• ChIP analysis has identified that KLF12 binds to the CACCC motif of the PD-L1 promoter

• KLF12 knockdown experiments demonstrate decreased PD-L1 transcription

• KLF12 physically interacts with P300, a histone acetyltransferase, affecting histone H3 acetylation at the PD-L1 promoter

Experimental Approaches:

• ChIP-seq analyses: Use KLF12 antibodies to map genome-wide binding sites, particularly in cancer cells with varying levels of immune checkpoint molecules

• Co-immunoprecipitation: Investigate physical interactions between KLF12 and other transcriptional regulators like P300, STAT1, and STAT3

• Immunohistochemistry: Examine correlation between KLF12 and PD-L1 expression patterns in patient tumor tissues

In vivo application: In immunocompetent mice, KLF12 knockout inhibits tumor growth and promotes infiltration of CD8+ T cells - a phenomenon not observed in immunodeficient mice .

This suggests targeting KLF12 may represent a potential therapeutic strategy for enhancing immunotherapy response in NSCLC by modulating PD-L1 expression.

How should ChIP experiments be designed to study KLF12 binding to gene promoters?

Designing effective ChIP experiments for KLF12 requires careful consideration of several parameters:

Experimental Design Elements:

Protocol considerations from published research:
Several successful ChIP experiments have been reported using KLF12 antibodies. For instance, researchers investigating KLF12's regulation of PD-L1 in NSCLC used ChIP analysis to demonstrate binding to the CACCC motif in the PD-L1 promoter . Similarly, studies of KLF12's role in breast cancer identified binding to the p21 promoter at three KLF12 binding sites (−1677 to −1671, −1589 to −1583, −1300 to −1294) .

For quantification, qPCR is typically used to measure enrichment relative to input and IgG control. More comprehensive analysis can be achieved through ChIP-seq approaches to identify genome-wide binding patterns of KLF12.

What methodological approaches are most effective for investigating KLF12's role in cardiac remodeling?

Recent research has identified KLF12 as an important regulator of angiotensin II-induced cardiac remodeling , necessitating specialized methodological approaches:

Model Systems:

• In vitro models: Primary cardiac fibroblasts, as KLF12 expression is primarily upregulated in cardiac fibroblasts during fibrotic response

• In vivo models:

  • Angiotensin II-induced cardiac remodeling in mice

  • Cardiac fibroblast-specific overexpression of KLF12 using lentivirus or miRNA (miR-1/133TS) technology

Key Methodological Approaches:

• Expression analysis: Quantify KLF12 upregulation in remodeling hearts using Western blot and qPCR

• Pathway analysis: RNA-seq to identify cardiac remodeling associated pathways affected by KLF12

• ChIP studies: Investigate KLF12 binding to the Smad7 promoter

• Functional assessment: Echocardiography to evaluate cardiac structure and function in animal models

Mechanistic insights:
Research has shown that KLF12 directly binds to the promoter of Smad7, leading to activation of the TGF-β-Smad3 pathway . This mechanistic insight suggests targeting KLF12 may represent a promising therapeutic approach for cardiac remodeling.

When designing experiments, it's important to note that effects appear more pronounced in male mice, indicating potential sex-specific differences that should be considered in experimental design .

What are the optimal conditions for using KLF12 antibodies in Western blotting?

Optimizing Western blot conditions for KLF12 detection requires attention to several key parameters:

Sample Preparation:

• For nuclear proteins like KLF12, consider specialized nuclear extraction protocols

• Load 15-50 μg of total protein per lane (validated ranges from published studies)

Electrophoresis and Transfer:

• Use 8-10% polyacrylamide gels for optimal separation around 65 kDa

• PVDF membranes generally provide better results than nitrocellulose for nuclear proteins

Antibody Conditions:

Detection Guidelines:

• Enhanced chemiluminescence (ECL) with exposure times of 1-5 minutes typically yields good results

• Expect band at approximately 65 kDa despite calculated molecular weight of 44 kDa

Controls:

• Positive control cell lines: Jurkat, 293T, HeLa whole cell lysates have been validated

• Include KLF12 knockdown samples when available to confirm specificity

Published Western blot data shows successful detection of KLF12 in Jurkat whole cell lysate at both 50 μg and 15 μg loading, as well as in 293T and HeLa whole cell lysates at 50 μg loading using ab129459 at 0.1 μg/mL with 3-minute exposure time .

How can researchers validate the specificity of KLF12 antibodies?

Validating antibody specificity is crucial for ensuring reliable experimental results. For KLF12 antibodies, consider these comprehensive validation approaches:

Genetic Validation Methods:

• Knockdown/Knockout studies: Compare antibody signal in:

  • Control vs. siRNA/shRNA KLF12 knockdown cells

  • Wild-type vs. CRISPR/Cas9 KLF12 knockout cells

• Overexpression validation: Compare signal in control vs. KLF12-overexpressing cells

Biochemical Validation Methods:

• Western blot analysis: Check for single band at expected MW (~65 kDa)

• Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding

• Multiple antibody validation: Use antibodies targeting different KLF12 epitopes

Application-specific validation:

Literature validation:
Several KLF12 antibodies have been extensively validated in published research. For instance, Proteintech's 13156-1-AP antibody has been cited in at least 8 publications for Western blot applications , while ab129459 has been cited in 10 publications .

When selecting an antibody, prioritize those with demonstrated specificity in your application of interest and consider performing independent validation when introducing a new antibody to your research.

What considerations are important when using KLF12 antibodies in ChIP experiments?

Chromatin immunoprecipitation (ChIP) is a powerful technique for studying KLF12's interaction with DNA. Several important considerations will maximize success:

Antibody Selection for ChIP:

• Choose antibodies specifically validated for ChIP applications

• Proteintech 13156-1-AP has been validated for ChIP applications in published studies

• Consider antibodies against tagged KLF12 constructs (e.g., His-tag, FLAG-tag) for recombinant systems

Protocol Optimization:

• Crosslinking: Typically 1% formaldehyde for 10 minutes at room temperature

• Sonication: Optimize to yield DNA fragments of 200-500 bp

• Immunoprecipitation buffers: Cell lysis buffer followed by nuclear lysis buffer containing protease inhibitors

• Antibody amount: Typically 2-5 μg per ChIP reaction

• Collection method: Protein G beads are commonly used to collect protein-DNA complexes

Controls and Validation:

• Input control: A portion of chromatin before immunoprecipitation

• IgG control: Matched isotype antibody at the same concentration

• Positive control region: Known KLF12 binding site

• Negative control region: Region not bound by KLF12

Known KLF12 Binding Sites:
KLF12 has been shown to bind to specific motifs in several gene promoters:

• CACCC motif in the PD-L1 promoter

• Three binding sites (−1677 to −1671, −1589 to −1583, −1300 to −1294) in the p21 promoter

• Promoter of Smad7 in cardiac fibroblasts

These validated binding sites can serve as positive controls when establishing ChIP protocols for KLF12 in your experimental system.

How can KLF12 antibodies be used to investigate protein-protein interactions in transcriptional complexes?

Investigating KLF12's interactions with other proteins is crucial for understanding its mechanisms of transcriptional regulation. Several approaches utilize KLF12 antibodies:

Co-Immunoprecipitation (Co-IP):

• Use KLF12 antibodies to pull down protein complexes

• Analyze by Western blot or mass spectrometry to identify interacting partners

• Example application: KLF12 antibodies have been used to demonstrate physical interaction with P300 histone acetyltransferase

Sequential ChIP (ChIP-reChIP):

• Perform first ChIP with KLF12 antibody

• Elute complexes and perform second ChIP with antibody against suspected interacting partner

• This approach has been used to investigate KLF12's interaction with p53 on the p21 promoter

Known KLF12 Interacting Proteins:

Methodological considerations:

• For co-IP, use mild lysis conditions to preserve protein-protein interactions

• Include appropriate controls (IgG, lysate input)

• Consider crosslinking approaches for transient or weak interactions

• Validate interactions through reciprocal co-IP (pull down with antibody against interacting partner)

Understanding KLF12's protein interactions provides crucial insights into its mechanisms of action in diverse biological contexts, from cancer progression to cardiac remodeling.